QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-initiates-coverage-on-olema-pharmaceuticals-with-buy-rating-announces-price-target-of-20

Guggenheim analyst Brad Canino initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Pri...

 oppenheimer-maintains-outperform-on-olema-pharmaceuticals-maintains-22-price-target

Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price ...

 jp-morgan-maintains-overweight-on-olema-pharmaceuticals-raises-price-target-to-29

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target fr...

 citigroup-maintains-buy-on-olema-pharmaceuticals-raises-price-target-to-21

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target fro...

 olema-pharmaceuticals-q2-eps-051-misses-038-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...

 goldman-sachs-maintains-buy-on-olema-pharmaceuticals-lowers-price-target-to-18

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from ...

 oppenheimer-maintains-outperform-on-olema-pharmaceuticals-lowers-price-target-to-22

Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price tar...

 olema-pharmaceuticals-q1-eps-036-beats-051-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-olema-pharmaceuticals-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 pri...

 jp-morgan-maintains-overweight-on-olema-pharmaceuticals-lowers-price-target-to-28

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target fr...

 olema-oncology-to-present-preclinical-data-for-op-3136-a-potent-kat6-inhibitor-demonstrating-anti-tumor-activity-in-multiple-solid-tumor-models-at-the-2025-aacr-annual-meeting

Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical com...

 oppenheimer-reiterates-outperform-on-olema-pharmaceuticals-lowers-price-target-to-25

Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price ta...

 hc-wainwright--co-reiterates-buy-on-olema-pharmaceuticals-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION